Document is current
Any future updates will be listed below
-
Authors
Reddy, Tejaswini
Puri, Akshjot
Guzman-Rojas, Liliana
Thomas, Christoforos https://orcid.org/0000-0003-3003-2954
Qian, Wei
Zhou, Jianying
Zhao, Hong https://orcid.org/0000-0001-8991-7824
Mahboubi, Bijan
Oo, Adrian
Cho, Young-Jae
Kim, Baek https://orcid.org/0000-0001-7986-4335
Thaiparambil, Jose
Rosato, Roberto https://orcid.org/0000-0002-7885-5127
Martinez, Karina Ortega
Chervo, Maria Florencia
Ayerbe, Camila
Giese, Noah https://orcid.org/0000-0002-0027-2239
Wink, David https://orcid.org/0000-0002-5652-7480
Lockett, Stephen
Wong, Stephen https://orcid.org/0000-0001-9188-6502
Chang, Jeffrey https://orcid.org/0000-0002-4578-5636
Krishnamurthy, Savitri
Yam, Clinton https://orcid.org/0000-0002-0809-0851
Moulder, Stacy
Piwnica-Worms, Helen https://orcid.org/0000-0003-4210-6738
Meric-Bernstam, Funda https://orcid.org/0000-0001-6816-6072
Chang, Jenny
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA284315, U01CA268813, U01CA268813, U01CA268813)
- License Information
-
More Information
Article History
Received: 9 May 2023
Accepted: 19 November 2024
First Online: 30 December 2024
Competing interests
: C. Yam reports grants from Conquer Cancer Foundation (Career Development Award supported by Fleur Fairman; the Gianni Bonadonna Breast Cancer Research Fellowship) and other support from MD Anderson Cancer Center (The University of Texas, Houston, TX) during the conduct of the study, as well as other support from Amgen, Merck, Genentech, and GSK outside the submitted work. S. Moulder also reports other support from Eli Lilly and Company and grants from ASCO Career Development Award Mentor outside the submitted work. J. Chang reports grants from the Cancer Prevention and Research Institute of Texas and from NIH during the conduct of the study. J.Chang is the sole inventor on patent application no. 10420838 entitled “Methods for treating cancer using iNOS-inhibitory compositions” held by Houston Methodist Hospital. C. Thomas reports support from NIH during this study. F. Meric-Bernstam reports grants and personal fees from F. Hoffmann-La Roche/Genentech during the conduct of the study, as well as personal fees from AbbVie, Aduro BioTech Inc., Alkermes, AstraZeneca, DebioPharm, eFFECTOR Therapeutics, IBM Watson, Infinity Pharmaceuticals, The Jackson Laboratory, Kolon Life Science, Lengo Therapeutics, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Samsung Bioepis, Seattle Genetics Inc., Tallac Therapeutics, Tyra Biosciences, Xencor, Zymeworks, Black Diamond, Biovica, Eisai, Immunomedics, Inflection Biosciences, Karyopharm Therapeutics, Loxo Oncology, Mersana Therapeutics, OnCusp Therapeutics, Puma Biotechnology Inc., Silverback Therapeutics, Spectrum Pharmaceuticals, and Zentalis and grants from Aileron Therapeutics, Inc., AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd., Debiopharm International, eFFECTOR Therapeutics, Guardant Health Inc., Klus Pharma, Takeda Pharmaceutical, Novartis, Puma Biotechnology Inc., and Taiho Pharmaceutical Co. outside the submitted work. No disclosures were reported by other authors.
